Search results for "LNCaP"

showing 10 items of 28 documents

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors

2015

Purpose The present study aims at developing and evaluating an urea-based prostate specific membrane antigen (PSMA) inhibitor suitable for labeling with 111In for SPECT and intraoperative applications as well as 68Ga and 64Cu for PET imaging. Methods The PSMA-based inhibitor-lysine-urea-glutamate-coupled to the spacer Phe-Phe-D-Lys(suberoyl) and functionalized with the enantiomerically pure prochelator (R)-1-(1-carboxy-3-carbotertbutoxypropyl)-4,7-carbotartbutoxymethyl)-1,4,7-triazacyclononane ((R)-NODAGA(tBu)3), to obtain (R)-NODAGA-Phe-Phe-D-Lys(suberoyl)-Lys-urea-Glu (CC34). CC34 was labeled with 111In, 68Ga and 64Cu. The radioconjugates were further evaluated in vitro and in vivo in LNC…

Glutamate Carboxypeptidase IIMaleBiodistributionPathologymedicine.medical_specialtylcsh:MedicineGallium RadioisotopesAcetatesurologic and male genital diseasesHeterocyclic Compounds 1-RingMicechemistry.chemical_compoundPharmacokineticsIn vivoLNCaPImage Processing Computer-AssistedTumor Cells CulturedGlutamate carboxypeptidase IImedicineAnimalsHumansTissue Distributionlcsh:ScienceIncubationMice Inbred BALB CMultidisciplinaryChemistrylcsh:RProstatic NeoplasmsXenograft Model Antitumor AssaysMolecular biologyIn vitroPositron-Emission TomographyAntigens SurfaceUreaFemalelcsh:QRadiopharmaceuticalsResearch ArticlePLOS ONE
researchProduct

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

2018

IL6/STAT3 signaling is associated with endocrine therapy resistance in prostate cancer, but therapies targeting this pathway in prostate cancer were unsuccessful in clinical trials so far. The mechanistic explanation for this phenomenon is currently unclear; however, IL6 has pleiotropic effects on a number of signaling pathways, including the androgen receptor (AR). Therefore, we investigated IL6-mediated AR activation in prostate cancer cell lines and ex vivo primary prostate tissue cultures in order to gain a better understanding on how to inhibit this process for future clinical trials. IL6 significantly increased androgen-dependent AR activity in LNCaP cells but importantly did not infl…

Male0301 basic medicineCancer ResearchINTERLEUKIN-6LactonesProstate cancerLIGAND-INDEPENDENT ACTIVATION0302 clinical medicineProstateDEPRIVATIONANDROGEN RECEPTORGLUCOCORTICOID-RECEPTORmedicine.anatomical_structureOncologyReceptors Androgen030220 oncology & carcinogenesisAndrogensSILTUXIMAB CNTO 328GROWTHSIGNAL TRANSDUCERSignal transductionLife Sciences & BiomedicineProtein BindingSignal TransductionSTAT3 Transcription FactorENZALUTAMIDEmedicine.drug_classMice NudeModels BiologicalTMPRSS203 medical and health sciencesProtein DomainsCell Line TumorLNCaPmedicineAnimalsHumansCastrationCANCER CELLSScience & TechnologyInterleukin-6business.industryProstatic NeoplasmsDNAmedicine.diseaseAndrogenXenograft Model Antitumor AssaysAndrogen receptor030104 developmental biologyCancer researchbusinessEx vivo
researchProduct

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines

2018

Neutrophil gelatinase-associated lipocalin (NGAL a.k.a lipocalin 2, lnc2) is a secreted protein which can form a complex with matrix metalloproteinase-9 (MMP9). This MMP9/NGAL complex has been associated with metastasis. MMP9 and NGAL are detected in the urine of patients afflicted with many different types of cancer, including prostate cancer. The effects of p53, NF-κB and the androgen receptor (AR) on the expression of NGAL was examined in four prostate cancer cell lines. Prostate cancer cell lines that are AR negative and expressed either mutant or no p53 (DU145 and PC3) displayed higher levels of NGAL expression compared to the prostate cancer cell lines (LNCaP and 22Rv-1) which are AR …

Male0301 basic medicinep53Cancer ResearchLipocalinMMP9Metastasis03 medical and health sciencesProstate cancerDU145GeneticCell Line Tumorandrogen receptorLNCaPGeneticsmedicineHumansNF-kappaBNGALMolecular BiologyChemistryNF-kappa BProstatic Neoplasmsmedicine.diseaseprostate cancerGene Expression Regulation NeoplasticAndrogen receptor030104 developmental biologyMatrix Metalloproteinase 9Receptors AndrogenCell cultureCancer researchMolecular MedicineTumor Suppressor Protein p53
researchProduct

Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.

1999

Phenylbutyrate (PB) is a potent differentiating agent and currently under investigation for the treatment of prostate cancer (CaP) and other malignancies. We have studied the impact of PB in vitro and in vivo on differentiation, proliferation and apoptosis in the LNCaP and LuCaP 23.1 prostate cancer xenograft models. In vitro we found that i) PB increased PSA secretion/cell, ii) inhibited cell proliferation in a time- and dose-dependent manner resulting in a cell cycle arrest in G1-phase and iii) induced apoptosis at concentrations of 2.5 mM after 3 days of treatment. In PB treated animals tumor growth stabilized or regressed. Combination of castration and PB treatment had a synergistic ant…

MaleCancer Researchmedicine.medical_specialtyProgrammed cell deathTransplantation HeterologousMice NudeAntineoplastic AgentsApoptosisBiologyPhenylbutyrateMiceProstate cancerIn vivoInternal medicineLNCaPTumor Cells CulturedmedicineAnimalsHumansMice Inbred BALB CCell growthCell CycleProstatic NeoplasmsCancerCell Differentiationmedicine.diseasePhenylbutyratesDisease Models AnimalEndocrinologyOncologyCancer cellAndrogensCancer researchCell DivisionNeoplasm TransplantationInternational Journal of Oncology
researchProduct

Polymeric Nanocarriers for Magnetic Targeted Drug Delivery: Preparation, Characterization, and in Vitro and in Vivo Evaluation

2013

In this paper the preparation of magnetic nano- carriers (MNCs), containing superparamagnetic domains, is reported, useful as potential magnetically targeted drug delivery systems. The preparation of MNCs was performed by using the PHEA-IB-p(BMA) graft copolymer as coating material through the homogenization−solvent evaporation method. Magnetic and nonmagnetic nanocarriers containing flutamide (FLU-MNCs) were prepared. The prepared nanocarriers have been exhaustively characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and magnetic measurements. Biological evaluation was performed by in vitro cytotoxicity and cell uptake tests and in vivo biodistribution …

MaleMaterials sciencePharmaceutical ScienceAntineoplastic AgentsNanotechnologyMagneticsDrug Delivery SystemsDynamic light scatteringIn vivoCell Line TumorDrug DiscoveryLNCaPAnimalsHumansDistribution (pharmacology)Tissue DistributionParticle SizeRats WistarMagnetite NanoparticlesDrug Carriersequipment and suppliesmagnetic nanocarrier magnetic targeting flutamide superparamagnetic nanoparticlesFlutamideIn vitroRatsTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsMolecular MedicineNanocarriersPeptideshuman activitiesSuperparamagnetismMolecular Pharmaceutics
researchProduct

Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific …

1997

Abstract Objectives To investigate the clinical value of human glandular kallikrein (hK2) reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of prostate cells in circulation and to compare the results with those obtained from prostate-specific antigen (PSA) RT-PCR. Methods We examined peripheral blood (PB) and bone marrow (BM) samples of 13 patients with advanced-stage prostate cancer and 63 patients with clinically localized disease for the presence of circulating prostate cells. An RT-PCR protocol with a two-step amplification cycle and hot-start conditions was used. Results The limit of detection of the PCR portion is similar for PSA and hK2 (5 to 10 copies of the pla…

MalePathologymedicine.medical_specialtyUrologyurologic and male genital diseasesPolymerase Chain ReactionPeripheral blood mononuclear cellProstate cancerAntigenProstateLNCaPHumansMedicineRNA MessengerHuman Glandular Kallikreinbusiness.industryProstatic NeoplasmsProstate-Specific AntigenNeoplastic Cells Circulatingmedicine.diseaseMolecular biologyProstate-specific antigenmedicine.anatomical_structureKallikreinsBone marrowbusinessTissue KallikreinsUrology
researchProduct

Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells.

2002

BACKGROUND Gap-junction-mediated intercellular communication (GJIC) is required for normal development and tissue homeostasis. However, the role of GJIC in human prostate carcinogenesis and progression remains ill-defined. METHODS The ability of hormones, anti-hormones, and the anti-hypertensive drug, forskolin, to restore GJIC in non-tumorigenic (RWPE-1 and PWR-1E) and malignant (RWPE-2, LNCaP, DU-145) human prostate epithelial cell lines, was examined by Scrape-Loading/Dye Transfer (SL/DT) and Fluorescence Recovery After Photobleaching (FRAP) methods using an Ultima laser cytometer. RESULTS Results from both assays show that PWR-1E, RWPE-2, LNCaP, and DU-145 cells have weak or absent GJIC…

Malemedicine.medical_specialtyEstroneUrologyCell CommunicationBiologyurologic and male genital diseasesmedicine.disease_causeConnexinschemistry.chemical_compoundProstate cancerCell–cell interactionInternal medicineLNCaPmedicineTumor Cells CulturedHumansTissue homeostasisForskolinColforsinGap JunctionsProstatic NeoplasmsEpithelial Cellsmedicine.diseaseEndocrinologyCell Transformation NeoplasticOncologychemistryCell cultureCancer researchCarcinogenesisImmortalised cell lineThe Prostate
researchProduct

Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer c…

1994

In order to better define potential mechanisms of growth regulation in human prostate cancer cells, we have compared biological responses (such as short-term response to both transforming growth factor alpha and beta; TFG alpha and TFG beta) in relation to hormone sensitivity of LNCaP, DU145, and PC3 cells. Androgen receptor (AR) and epidermal growth factor receptor (EGF-R) content of each cell line was also investigated. In addition, expression of EGF, TGF alpha, and TGF beta was evaluated through immunofluorescent staining. Growth of androgen non-responsive PC3 cells was stimulated by TGF alpha (about 35%) and inhibited by TGF beta (more than 50%), with respect to controls, after 48 h exp…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentClinical BiochemistryFluorescent Antibody Techniqueurologic and male genital diseasesBiochemistryProstate cancerEndocrinologyDU145Transforming Growth Factor betaInternal medicineLNCaPTumor Cells CulturedmedicineHumansReceptors Growth FactorEpidermal growth factor receptorMolecular BiologyPharmacologybiologyGrowth factorOrganic ChemistryProstatic NeoplasmsTransforming Growth Factor alphamedicine.diseaseAndrogen receptorEndocrinologyReceptors AndrogenCancer cellAndrogensbiology.proteinCell DivisionTransforming growth factorSteroids
researchProduct

Steroid-growth factor interaction in human prostate cancer. 2. Effects of transforming growth factors on androgen metabolism of prostate cancer cells

1996

The ability of human prostate cancer cells to metabolize androgens was assessed through administration of physiological concentration (0.5-10 nM) of tritiated testosterone (T) as precursor and one-step analysis of both T degradation and products' formation by reverse-phase HPLC and on-line radioactive detection after either 24 h or 72 h incubation. Overall, different prostate cancer cells degraded T quite differently, favoring alternatively reductive or oxidative metabolic pathways. In particular, both LNCaP and DU145 cells retained high levels of unconverted T, with a limited production of androstenedione and its 17-keto derivatives and relatively high amounts of dihydrotestosterone (DHT) …

Malemedicine.medical_specialtymedicine.drug_classClinical BiochemistryBiologyurologic and male genital diseasesBiochemistrychemistry.chemical_compoundEndocrinologyDU145Transforming Growth Factor betaInternal medicineLNCaPTumor Cells CulturedmedicineHumansMolecular BiologyTestosteronePharmacologyAndrosteroneOrganic ChemistryProstatic NeoplasmsTransforming Growth Factor alphaAndrogenEndocrinologychemistryDihydrotestosteroneCancer cellAndrogensmedicine.drugTransforming growth factorSteroids
researchProduct

Upconversion Nanocarriers Encapsulated with Photoactivatable Ru Complexes for Near-Infrared Light-Regulated Enzyme Activity.

2017

Enzyme activity is important for metabolism, cell functions, and treating diseases. However, remote control of enzyme activity in deep tissue remains a challenge. This study demonstrates near-infrared (NIR) light-regulated enzyme activity in living cells based on upconverting nanoparticles (UCNPs) and a photoactivatable Ru complex. The Ru complex is a caged enzyme inhibitor that can be activated by blue light. To prepare a nanocarrier for NIR photoinhibition of enzyme activity, a UCNP and the caged enzyme inhibitors are encapsulated in a hollow mesoporous silica nanoparticle. In such a nanocarrier, the UCNP can harvest NIR light and convert it into blue light, which can activate the caged e…

Materials scienceCell SurvivalInfrared RaysCathepsin KNanoparticle02 engineering and technology010402 general chemistryPhotochemistry01 natural sciencesRutheniumBiomaterialsCell Line TumorLNCaPHumansGeneral Materials ScienceEnzyme Inhibitorsneoplasmschemistry.chemical_classificationbiologytechnology industry and agricultureGeneral ChemistryMesoporous silicaequipment and supplies021001 nanoscience & nanotechnologyPhoton upconversionEnzyme assay0104 chemical sciencesEnzymechemistryEnzyme inhibitorbiology.proteinNanoparticlesNanocarriers0210 nano-technologyBiotechnologySmall (Weinheim an der Bergstrasse, Germany)
researchProduct